Empagliflozin and kidney outcomes in Asian patients with type 2 diabetes and established cardiovascular disease: Results from the EMPA‐REG OUTCOME® trial

by Takashi Kadowaki, Masaomi Nangaku, Stefan Hantel, Tomoo Okamura, Maximilian vonEynatten, Christoph Wanner, Audrey Koitka‐Weber
Published 2019-05-01

Nephrotic-range proteinuria in type 2 diabetes: Effects of empagliflozin on kidney disease progression and clinical outcomes

by Piero Ruggenenti, Bettina J. Kraus, Silvio E. Inzucchi, Bernard Zinman, Stefan Hantel, Michaela Mattheus, Maximilian von Eynatten, Giuseppe Remuzzi, Audrey Koitka-Weber, Christoph Wanner
Published 2022-01-01

Short‐Term Changes in Albuminuria and Risk of Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus: A Post Hoc Analysis of the EMPA‐REG OUTCOME Trial

by Simke W. Waijer, Di Xie, Silvio E. Inzucchi, Bernard Zinman, Audrey Koitka‐Weber, Michaela Mattheus, Maximillian von Eynatten, Lesley A. Inker, Christoph Wanner, Hiddo J. L. Heerspink
Published 2020-09-01

Cardio/Kidney Composite End Points: A Post Hoc Analysis of the EMPA‐REG OUTCOME Trial

by João Pedro Ferreira, Bettina Johanna Kraus, Isabella Zwiener, Sabine Lauer, Bernard Zinman, David H. Fitchett, Audrey Koitka‐Weber, Jyothis T. George, Anne Pernille Ofstad, Christoph Wanner, Faiez Zannad
Published 2021-04-01

Disparate Effects of Diabetes and Hyperlipidemia on Experimental Kidney Disease

by Anna M. D. Watson, Anna M. D. Watson, Eleanor A. M. Gould, Sarah C. Moody, Priyadharshini Sivakumaran, Karly C. Sourris, Bryna S. M. Chow, Audrey Koïtka-Weber, Terri J. Allen, Karin A. M. Jandeleit-Dahm, Karin A. M. Jandeleit-Dahm, Mark E. Cooper, Mark E. Cooper, Anna C. Calkin, Anna C. Calkin
Published 2020-06-01